Interview: New But Not News –A Smooth Transition To USP <382> With Established Expertise

A major update to injectable system regulation introduces a more comprehensive approach to evaluating elastomeric components used in vials, cartridges, and prefilled syringes. Unlike previous standards, which focused mainly on individual component testing, the new framework requires full-system assessment using the final drug product or a validated proxy. This ensures that factors such as container closure integrity, functional performance, and usability are measured under conditions that reflect true, real‑world use. The change also shifts greater responsibility to drug developers, who must now demonstrate that their complete drug‑device combination maintains sterility, performs consistently, and meets the needs of its intended patient population. While the expanded requirements may initially seem demanding—especially for smaller organizations—the transition is supported by established methodologies, advanced testing capabilities, and expertise developed through years of full-system evaluation.

Ultimately, these updates aim to improve patient safety, strengthen regulatory submissions, and streamline the development of effective injectable therapies.